First-in-Human Trial of ACP-501 for Familial LCAT Deficiency Initiated
A clinical trial has been initiated to evaluate the safety and efficacy of ACP-501, a recombinant human LCAT, in a patient with familial LCAT deficiency.
Asset / Drug
Drug and asset intelligence for ACP-501 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Enzyme Replacement Therapy
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.